|
1
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villanueva A, Minguez B, Forner A, Reig M
and Llovet JM: Hepatocellular carcinoma: Novel molecular approaches
for diagnosis, prognosis, and therapy. Annu Rev Med. 61:317–328.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McClune AC and Tong MJ: Chronic Hepatitis
B and hepatocellular carcinoma. Clin Liver Dis. 14:461–476. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen CJ and Chen DS: Interaction of
hepatitis B virus, chemical carcinogen, and genetic susceptibility:
Multistage hepatocarcinogenesis with multifactorial etiology.
Hepatology. 36:1046–1049. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aravalli RN, Steer CJ and Cressman EN:
Molecular mechanisms of hepatocellular carcinoma. Hepatology.
48:2047–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kan Z, Zheng H, Liu X, Li S, Barber TD,
Gong Z, Gao H, Hao K, Willard MD, Xu J, et al: Whole-genome
sequencing identifies recurrent mutations in hepatocellular
carcinoma. Genome Res. 23:1422–1433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murphy D, Detjen KM, Welzel M, Wiedenmann
B and Rosewicz S: Interferon-alpha delays S-phase progression in
human hepatocellular carcinoma cells via inhibition of specific
cyclin-dependent kinases. Hepatology. 33:346–356. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subramaniam A, Shanmugam MK, Ong TH, Li F,
Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al:
Emodin inhibits growth and induces apoptosis in an orthotopic
hepatocellular carcinoma model by blocking activation of STAT3. Br
J Pharmacol. 170:807–821. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilks AF, Harpur AG, Kurban RR, Ralph SJ,
Zürcher G and Ziemiecki A: Two novel protein-tyrosine kinases, each
with a second phosphotransferase-related catalytic domain, define a
new class of protein kinase. Mol Cell Biol. 11:2057–2065. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rane SG and Reddy EP: Janus kinases:
Components of multiple signaling pathways. Oncogene. 19:5662–5679.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Staerk J, Kallin A, Demoulin JB,
Vainchenker W and Constantinescu SN: JAK1 and Tyk2 activation by
the homologous polycythemia vera JAK2 V617F mutation: Cross-talk
with IGF1 receptor. J Biol Chem. 280:41893–41899. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK,
Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, et al: Mutational analysis
of JAK1 gene in human hepatocellular carcinoma. Neoplasma.
56:136–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang S, Luo C, Gu Q, Xu Q, Wang G, Sun H,
Qian Z, Tan Y, Qin Y, Shen Y, et al: Activating JAK1 mutation may
predict the sensitivity of JAK-STAT inhibition in hepatocellular
carcinoma. Oncotarget. 7:5461–5469. 2016.PubMed/NCBI
|
|
14
|
Zhou C, Yu Q, Chen L, Wang J, Zheng S and
Zhang J: A miR-1231 binding site polymorphism in the 3′ UTR of
IFNAR1 is associated with hepatocellular carcinoma susceptibility.
Gene. 507:95–98. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin Y, Yu Q, Zhou D, Chen L, Huang X, Xu
G, Huang J, Gao X, Gao Y and Shen L: The Mitochondrial DNA 9-bp
deletion polymorphism as a risk factor for hepatocellular carcinoma
in the Chinese population. Genet Test Mol Biomarkers. 16:330–334.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu Q, Zhou CX, Chen NS, Zheng SD, Shen LM
and Zhang JK: A polymorphism within ErbB4 is associated with risk
for hepatocellular carcinoma in Chinese population. World J
Gastroenterol. 18:383–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allen RC, Graves G and Budowle B:
Polymerase chain reaction amplification products separated on
rehydratable polyacrylamide gels and stained with silver.
Biotechniques. 7:736–744. 1989.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta DeltaC(t)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yeh TC and Pellegrini S: The Janus kinase
family of protein tyrosine kinases and their role in signaling.
Cell Mol Life Sci. 55:1523–1534. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nordqvist C: Protein JAK makes cancer
cells contract, so they can squeeze out of a tumor. Medical News
Today. 2011.
|
|
23
|
Quintás-Cardama A, Kantarjian H, Cortes J
and Verstovsek S: Janus kinase inhibitors for the treatment of
myeloproliferative neoplasias and beyond. Nat Rev Drug Discov.
10:127–140. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu
Y, Guo B, Shen Y, Landi D, et al: An insertion/deletion
polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′
untranslated region confers risk for hepatocellular carcinoma.
Carcinogenesis. 30:2064–2069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang B, Yang H, Shen L, Wang J, Pu W, Chen
Z, Shen X, Fu J and Zhuang Z: Rs56288038 (C/G) in 3′UTR of IRF-1
regulated by MiR-502-5p promotes gastric cancer development. Cell
Physiol Biochem. 40:391–399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan Y, Qian X and Zhang C: U/G SNP
rs111904020 in 3′UTR of STAT3 regulated by miR-214 promotes
hepatocellular carcinoma development in Chinese population. Tumour
Biol. 37:14629–14635. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma J, Guo R, Wang T, Pan X and Lei X:
Let-7b binding site polymorphism in the B-cell lymphoma-extra large
3′UTR is associated with fluorouracil resistance of hepatocellular
carcinoma. Mol Med Rep. 11:677–681. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang C, Zhao H, Zhao X, Wan J, Wang D, Bi
W, Jiang X and Gao Y: Association between an insertion/deletion
polymorphism within 3′UTR of SGSM3 and risk of hepatocellular
carcinoma. Tumour Biol. 35:295–301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wheeler G, Ntounia-Fousara S, Granda B,
Rathjen T and Dalmay T: Identification of new central nervous
system specific mouse microRNAs. FEBS Lett. 580:2195–2200. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanaan Z, Roberts H, Eichenberger MR,
Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and
Galandiuk S: A plasma microRNA panel for detection of colorectal
adenomas: A step toward more precise screening for colorectal
cancer. Ann Surg. 258:400–408. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanaka T, Arai M, Jiang X, Sugaya S, Kanda
T, Fujii K, Kita K, Sugita K, Imazeki F, Miyashita T, et al:
Downregulation of microRNA-431 by human interferon-beta inhibits
viability of medulloblastoma and glioblastoma cells via
upregulation of SOCS6. Int J Oncol. 44:1685–1690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fang L, Du WW, Yang X, Chen K, Ghanekar A,
Levy G, Yang W, Yee AJ, Lu WY, Xuan JW, et al: Versican
3′-untranslated region (3′-UTR) functions as a ceRNA in inducing
the development of hepatocellular carcinoma by regulating miRNA
activity. FASEB J. 27:907–919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun K, Zeng T, Huang D, Liu Z, Huang S,
Liu J and Qu Z: MicroRNA-431 inhibits migration and invasion of
hepatocellular carcinoma cells by targeting the ZEB1-mediated
epithelial-mensenchymal transition. FEBS Open Bio. 5:900–907. 2015.
View Article : Google Scholar : PubMed/NCBI
|
